Delivery Order SPE2DB24D2003-SPE2DB25FXLL7
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $6,244.42 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablet unit dose packages (16 count) on September 8, 2025, with completion expected by September 9, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of the company's pharmaceutical supply support to federal military and healthcare systems. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $1,375.92 firm fixed-price delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging, quantity 16 units. The contract is set to complete by June 3, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging (16 count) with a contract ceiling value of $4,734.66. This is a firm fixed-price delivery order with an ultimate completion date of August 7, 2025, representing a competitively awarded contract with no set-aside designation. The performance location is AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging of 10 units, with a ceiling value of $18,754.48. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 10, 2025. The award is performed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a...
- The Defense Logistics Agency awarded a delivery order valued at $1,856.58 to AmerisourceBergen Drug Corp for UBRELVY 50 MG tablets (10 unit doses) on September 10, 2025, with an ultimate completion date of September 11, 2025. This firm fixed-price delivery order represents a non-set-aside, competitively awarded contract under the company's broader pharmaceutical supply agreement. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 4,568,984,056 units of UBRELVY 100 mg tablets in unit dose packages of 16 tablets, valued at $59,129.24. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of August 5, 2025, and is being fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment medication, and this delivery order represents fulfillment...
- The Defense Logistics Agency awarded a delivery order valued at $1,048.62 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16 unit-dose tablets) on July 25, 2025, with an ultimate completion date of July 28, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor, with performance occurring at its corporate office location in the same city....
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $22,277.22 by the Defense Logistics Agency for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging of 10s. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of July 31, 2025. The award was executed on July 30, 2025, and represents a child contract under AmerisourceBergen's larger relationship with DLA as a...
- The Defense Logistics Agency awarded a delivery order valued at $1,217.32 to AmerisourceBergen Drug Corp for UBRELVY 50 mg tablets (10 unit dose packages) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed price delivery order represents a non-set-aside competitive award and reflects the pharmaceutical distribution services AmerisourceBergen provides to federal medical procurement. The place of performance is located in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for UBRELVY (Ubrogepant) 100 mg tablets, unit dose packages of 10, valued at $1,158.25 with a firm fixed price structure. This award, issued on July 21, 2025, represents a non-set-aside competitive delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be delivered to the contractor's distribution facility in Conshohocken,...
- SPE2DB24D2003Indefinite Delivery Contract
- SPE2DB24D2003-SPE2DB25FXLL7Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,338.57 to AmerisourceBergen Drug Corp for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging, quantities of 16. This contract represents a firm fixed-price delivery order with an ultimate completion date of August 8, 2025, and was competitively awarded without set-aside designation. The pharmaceutical will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. This prime contract vehicle serves as a comprehensive global pharmaceutical support mechanism enabling AmerisourceBergen to supply a diverse range of pharmaceuticals and medical supplies to support military healthcare programs worldwide. UBRELVY, a migraine treatment medication, falls within the company's extensive portfolio of brand-name and generic pharmaceuticals delivered through the DLA's Medical Supply Chain to support Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.3k | 8/7/25 |